Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07WTG
|
|||
| Former ID |
DIB001627
|
|||
| Drug Name |
Recombinant acidic fibroblast growth factor
|
|||
| Synonyms |
AFGF; Rh-aFGF; Recombinant acidic fibroblast growth factor (ulcer/burns); Recombinant acidic fibroblast growth factor (ulcer/burns), SinoBiomed; Recombinant acidic fibroplast growth factor (ulcer/burns), SinoBiomed
Click to Show/Hide
|
|||
| Indication | Skin burns [ICD-11: ME65.0] | Phase 3 | [1] | |
| Company |
SinoBiomed Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fibroblast growth factor (FGF) | Target Info | Modulator | [2], [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Pharmacokinetic Properties of 2nd-Generation Fibroblast Growth Factor-1 Mutants for Therapeutic Application. November 1, 2012. | |||
| REF 2 | Molecular characterization of recombinant human acidic fibroblast growth factor produced in E. coli: comparative studies with human basic fibroblast growth factor. Mol Endocrinol. 1990 Jun;4(6):869-79. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.